KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2025)

Aurinia Pharmaceuticals' Capital Leases history spans 3 years, with the latest figure at $52.3 million for Q4 2025.

  • For Q4 2025, Capital Leases fell 10.64% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $52.3 million, down 10.64%, while the annual FY2025 figure was $52.3 million, 10.64% down from the prior year.
  • Capital Leases reached $52.3 million in Q4 2025 per AUPH's latest filing, down from $55.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $79.4 million in Q2 2023 to a low of $52.3 million in Q4 2025.
  • Average Capital Leases over 3 years is $64.4 million, with a median of $64.9 million recorded in 2024.
  • The largest YoY upside for Capital Leases was 8.64% in 2024 against a maximum downside of 22.42% in 2024.
  • A 3-year view of Capital Leases shows it stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024, then decreased by 10.64% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Capital Leases are $52.3 million (Q4 2025), $55.7 million (Q3 2025), and $59.3 million (Q2 2025).